pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,322 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech92BioSpace91raps37globenewswire health28fda recalls
therapy area
allOncology4988Rare Disease818Hematology759Cardiology716Immunology715Psychiatry & CNS579Pulmonology
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
    BioPharma Dive · 2mo ago↗ source
  • Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery
    The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.
    onclive · 2mo ago↗ source
  • STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
    Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.
← prev
page 46 of 53
next →
22
fda press21
fda medwatch17
570
Vaccines505
Endocrinology & Metabolism288
Ophthalmology254
Infectious Disease238
Nephrology227
STAT · 2mo ago
↗ source
  • Novo hikes guidance on Wegovy pill’s fast sales start
    In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
    BioPharma Dive · 2mo ago↗ source
  • Why the FDA is authorizing fruit-flavored vapes
    Marty Makary says he was "skeptical initially" about flavored vapes but that age-gating technology could limit their use.
    STAT · 2mo ago↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 2mo ago↗ source
  • Avalo shares spike on skin drug data; BioNTech to cut staff
    Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: When the path to good AI is littered with bad data
    In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
    STAT · 2mo ago↗ source
  • ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
    Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
    onclive · 2mo ago↗ source
  • STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
    Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
    One of the most powerful pharmaceutical lobbying groups is launching a new seven-figure advertising blitz targeting a federal drug discount program
    STAT · 2mo ago↗ source
  • Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management
    Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.
    onclive · 2mo ago↗ source
  • Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration
    New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
    onclive · 2mo ago↗ source
  • Disease Assessment and Mutational Testing in Progressive CLL
    Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.
    onclive · 2mo ago↗ source
  • Clinical Scenario Presentation and Treatment Approach for Progressive Disease
    Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.
    onclive · 2mo ago↗ source
  • Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
    Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.
    onclive · 2mo ago↗ source
  • Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026
    SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.
    onclive · 2mo ago↗ source
  • HHS tackles ‘overmedication’
    The cruise ship hantavirus outbreak, 988 staffing problems, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
    A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
    BioPharma Dive · 2mo ago↗ source
  • Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia care
    Ambiguous loss is at the heart of the dementia illness experience.
    STAT · 2mo ago↗ source
  • Opinion: Dr. Glaucomflecken wants to make a stink
    “They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.
    STAT · 2mo ago↗ source
  • STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
    Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
    STAT · 2mo ago↗ source
  • STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations
    Policy recommendations in OpenAI's blueprint for unlocking AI’s potential to change health care are reasonable, but also self-serving, experts say.
    STAT · 2mo ago↗ source
  • Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
    The psychedelics field is getting what it has long wanted. Now it has to step up.
    STAT · 2mo ago↗ source
  • Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC
    Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.
    onclive · 2mo ago↗ source